Tomas Forslund

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2023;32(11):1223-1232

Heterogeneity after harmonisation: A retrospective cohort study of bleeding and stroke risk after the introduction of direct oral anticoagulants in four Western European countries

Komen JJ; Hunt NB; Pottegard A; Hjemdahl P; Wettermark B; Olesen M; Bennie M; Mueller T; Carragher R; Karlstad O; Kjerpeseth LJ; Klungel OH; Forslund T
Article: EUROPEAN HEART JOURNAL. 2022;43(37):3528-3538

Oral anticoagulants in patients with atrial fibrillation at low stroke risk: a multicentre observational study

Komen JJ; Pottegard A; Mantel-Teeuwisse AK; Forslund T; Hjemdahl P; Wettermark B; Hallas J; Olesen M; Bennie M; Mueller T; Carragher R; Karlstad O; Kjerpeseth LJ; Klungel OH
Article: HEART. 2022;108(8):613-618

Non-vitamin K antagonist oral anticoagulants, proton pump inhibitors and gastrointestinal bleeds

Komen J; Pottegard A; Hjemdahl P; Mantel-Teeuwisse AK; Wettermark B; Hellfritzsch M; Hallas J; Herings R; Smits L; Forslund T; Klungel O
Article: EUROPACE. 2021;23(11):1722-1730

Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries

Komen JJ; Pottegard A; Mantel-Teeuwisse AK; Forslund T; Hjemdahl P; Wettermark B; Hellfritzsch M; Hallas J; Olesen M; Bennie M; Mueller T; Voss A; Schink T; Haug U; Kollhorst B; Karlstad O; Kjerpeseth LJ; Klungel OH
Article: JOURNAL OF THE AMERICAN HEART ASSOCIATION. 2021;10(16):e021716

Early Risk of Stroke in Patients Undergoing Acute Versus Elective Cardioversion for Atrial Fibrillation

Forslund T; Braunschweig F; Holzmann MJ; Siddiqui AJ
Article: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2021;30(7):934-951

Greedy caliper propensity score matching can yield variable estimates of the treatment-outcome association-A simulation study

Komen JJ; Belitser SV; Wyss R; Schneeweiss S; Taams AC; Pajouheshnia R; Forslund T; Klungel OH
Article: EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY. 2021;7(F11):f72-f80

Long-term persistence and adherence with non-vitamin K oral anticoagulants in patients with atrial fibrillation and their associations with stroke risk

Komen JJ; Heerdink ER; Klungel OH; Mantel-Teeuwisse AK; Forslund T; Wettermark B; Hjemdahl P
Article: FAMILY PRACTICE. 2021;38(2):132-140

Patterns of multimorbidity and pharmacotherapy: a total population cross-sectional study

Forslund T; Carlsson AC; Ljunggren G; Arnlov J; Wachtler C
Article: EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY. 2021;7(1):3-10

Association of preceding antithrombotic therapy in atrial fibrillation patients with ischaemic stroke, intracranial haemorrhage, or gastrointestinal bleed and mortality

Komen JJ; Forslund T; Mantel-Teeuwisse AK; Klungel OH; von Euler M; Braunschweig F; Wallen H; Hjemdahl P
Article: BMC PSYCHIATRY. 2020;20(1):328

Trends in psychiatric diagnoses, medications and psychological therapies in a large Swedish region: a population-based study

Forslund T; Kosidou K; Wicks S; Dalman C
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2020;107(1):287-294

Concomitant Anticoagulant and Antidepressant Therapy in Atrial Fibrillation Patients and Risk of Stroke and Bleeding

Komen JJ; Hjemdahl P; Mantel-Teeuwisse AK; Klungel OH; Wettermark B; Forslund T
Article: JOURNAL OF THROMBOSIS AND THROMBOLYSIS. 2019;48(4):668-673

Venous thromboembolism 2011-2018 in Stockholm: a demographic study

Wandell P; Forslund T; Danin Mankowitz H; Ugarph-Morawski A; Eliasson S; Braunschwieg F; Holmstrom M
Article: STROKE. 2018;49(9):2122-2128

Improved Stroke Prevention in Atrial Fibrillation After the Introduction of Non-Vitamin K Antagonist Oral Anticoagulants The Stockholm Experience

Forslund T; Komen JJ; Andersen M; Wettermark B; von Euler M; Mantel-Teeuwisse AK; Braunschweig F; Hjemdahl P
Article: EUROPACE. 2018;20(3):420-428

Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study

Forslund T; Wettermark B; Andersen M; Hjemdahl P
Article: AMERICAN JOURNAL OF CARDIOLOGY. 2017;120(8):1302-1308

Sex and Gender Differences in Thromboprophylactic Treatment of Patients With Atrial Fibrillation After the Introduction of Non-Vitamin K Oral Anticoagulants

Loikas D; Forslund T; Wettermark B; Schenck-Gustafsson K; Hjemdahl P; von Euler M
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2017;73(10):1315-1322

Factors associated with antithrombotic treatment decisions for stroke prevention in atrial fibrillation in the Stockholm region after the introduction of NOACs

Komen J; Forslund T; Hjemdahl P; Wettermark B
Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2017;83(3):642-652

Effects of policy interventions on the introduction of novel oral anticoagulants in Stockholm: an interrupted time series analysis

Komen J; Forslund T; Hjemdahl P; Andersen M; Wettermark B
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2016;72(3):329-338

Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation

Forslund T; Wettermark B; Hjemdahl P
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2014;70(12):1477-1485

Risks for stroke and bleeding with warfarin or aspirin treatment in patients with atrial fibrillation at different CHA₂DS₂VASc scores: experience from the Stockholm region

Forslund T; Wettermark B; Wandell P; von Euler M; Hasselstrom J; Hjemdahl P
Article: INTERNATIONAL JOURNAL OF CARDIOLOGY. 2013;170(2):208-214

Risk scoring and thromboprophylactic treatment of patients with atrial fibrillation with and without access to primary healthcare data: Experience from the Stockholm health care system

Forslund T; Wettermark B; Wandell P; von Euler M; Hasselstrom J; Hjemdahl P
Article: JOURNAL OF OBESITY. 2011;2011:459263-7

Usage, risk, and benefit of weight-loss drugs in primary care.

Forslund T; Raaschou P; Hjemdahl P; Krakau I; Wettermark B
Article: LAKARTIDNINGEN. 2010;107(13-14):910-913

[Anti-obesity agents do not seem to have any beneficial effects. Health centers prescribe preparations haphazardly, according to a medical records study].

Forslund T; Wettermark B; Raaschou P; Hjemdahl P; Krakau I
Visa fler

Alla övriga publikationer

Letter: EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY. 2021;7(3):e31

Themultiplication of loaves and fishes approach: a critic to double anti-thrombotics or to double number of ischaemic events? Response

Komen JJ; Forslund T; Mantel-Teeuwisse AK; Klungel OH; von Euler M; Braunschweig F; Wallen H; Hjemdahl P
Review: LAKARTIDNINGEN. 2018;115:FAH6

[Improved stroke prevention in atrial fibrillation: the Stockholm experience of the introduction of NOACs].

Hjemdahl P; Braunschweig F; Holmström M; Johnsson H; von Euler M; Wallén H; Forslund T
Thesis / dissertation: 2017

Antithrombotic treatment of atrial fibrillation before and after the introduction of non-vitamin K antagonist oral anticoagulants (NOAC) in the Stockholm health care region

Forslund, Tomas
Review: LAKARTIDNINGEN. 2015;112:CZYS

[More with atrial fibrillation, anticoagulants since the coming of NOAK ].

Forslund T; von Euler M; Johnsson H; Holmström M; Wettermark B; Hjemdahl P

Anställningar

Anknuten till Forskning, Neurobiologi, vårdvetenskap och samhälle, Karolinska Institutet, 2024-2027

Examina och utbildning

Medicine Doktorsexamen, Institutionen för medicin, Solna, Karolinska Institutet, 2017
Läkarexamen, Karolinska Institutet, 2002

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI